Algert Global LLC Boosts Stake in Vera Therapeutics

Institutional investor increases holdings in biotech firm by 15.4% in Q3

Mar. 17, 2026 at 7:09am

Got story updates? Submit your updates here. ›

Algert Global LLC, an investment management firm, has increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 15.4% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission. The fund now owns 293,388 shares of the biopharmaceutical company's stock, valued at $8.5 million.

Why it matters

Vera Therapeutics is a clinical-stage biotech company focused on developing novel immunotherapies to treat autoimmune and inflammatory diseases. The increase in Algert Global's stake suggests the firm sees potential in Vera's pipeline and future growth prospects.

The details

According to the 13F filing, Algert Global acquired an additional 39,235 shares of Vera Therapeutics during the third quarter, bringing its total ownership to 0.46% of the company's outstanding shares. The investment firm cited Vera's promising drug candidates and the potential for the company's proprietary protein engineering platform to yield new therapeutic approaches.

  • Algert Global increased its stake in Vera Therapeutics during the third quarter of 2026.

The players

Algert Global LLC

An investment management firm that has increased its holdings in Vera Therapeutics, a clinical-stage biotech company.

Vera Therapeutics, Inc.

A biopharmaceutical company focused on developing novel immunotherapies to treat autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

The increase in Algert Global's stake in Vera Therapeutics suggests the investment firm sees significant potential in the biotech company's pipeline and technology platform, which could signal positive developments for the company's future growth and drug development efforts.